Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry

T. A. Kato, Y. Yamauchi, H. Horikawa, A. Monji, Y. Mizoguchi, Y. Seki, K. Hayakawa, H. Utsumi, S. Kanba

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.

Original languageEnglish
Pages (from-to)331-344
Number of pages14
JournalCurrent Medicinal Chemistry
Volume20
Issue number3
Publication statusPublished - Jan 1 2013

Fingerprint

Psychotropic Drugs
Microglia
Neurotransmitter Agents
Psychiatry
Antidepressive Agents
Antipsychotic Agents
Dopamine
Brain
Serotonin
Animals
Neurotransmitter Transport Proteins
Imaging techniques
Neurotransmitter Receptor
Positron emission tomography
Brain Diseases
Pathology
Autistic Disorder
Positron-Emission Tomography
Anticonvulsants
Synapses

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Kato, T. A., Yamauchi, Y., Horikawa, H., Monji, A., Mizoguchi, Y., Seki, Y., ... Kanba, S. (2013). Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry. Current Medicinal Chemistry, 20(3), 331-344.

Neurotransmitters, psychotropic drugs and microglia : Clinical implications for psychiatry. / Kato, T. A.; Yamauchi, Y.; Horikawa, H.; Monji, A.; Mizoguchi, Y.; Seki, Y.; Hayakawa, K.; Utsumi, H.; Kanba, S.

In: Current Medicinal Chemistry, Vol. 20, No. 3, 01.01.2013, p. 331-344.

Research output: Contribution to journalArticle

Kato, TA, Yamauchi, Y, Horikawa, H, Monji, A, Mizoguchi, Y, Seki, Y, Hayakawa, K, Utsumi, H & Kanba, S 2013, 'Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry', Current Medicinal Chemistry, vol. 20, no. 3, pp. 331-344.
Kato TA, Yamauchi Y, Horikawa H, Monji A, Mizoguchi Y, Seki Y et al. Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry. Current Medicinal Chemistry. 2013 Jan 1;20(3):331-344.
Kato, T. A. ; Yamauchi, Y. ; Horikawa, H. ; Monji, A. ; Mizoguchi, Y. ; Seki, Y. ; Hayakawa, K. ; Utsumi, H. ; Kanba, S. / Neurotransmitters, psychotropic drugs and microglia : Clinical implications for psychiatry. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 3. pp. 331-344.
@article{e8baef2402a84be38adea3e4b0dddf87,
title = "Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry",
abstract = "Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.",
author = "Kato, {T. A.} and Y. Yamauchi and H. Horikawa and A. Monji and Y. Mizoguchi and Y. Seki and K. Hayakawa and H. Utsumi and S. Kanba",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "20",
pages = "331--344",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Neurotransmitters, psychotropic drugs and microglia

T2 - Clinical implications for psychiatry

AU - Kato, T. A.

AU - Yamauchi, Y.

AU - Horikawa, H.

AU - Monji, A.

AU - Mizoguchi, Y.

AU - Seki, Y.

AU - Hayakawa, K.

AU - Utsumi, H.

AU - Kanba, S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.

AB - Psychiatric disorders have long and dominantly been regarded to be induced by disturbances of neuronal networks including synapses and neurotransmitters. Thus, the effects of psychotropic drugs such as antipsychotics and antidepressants have been understood to modulate synaptic regulation via receptors and transporters of neurotransmitters such as dopamine and serotonin. Recently, microglia, immunological/inflammatory cells in the brain, have been indicated to have positive links to psychiatric disorders. Positron emission tomography (PET) imaging and postmortem studies have revealed microglial activation in the brain of neuropsychiatric disorders such as schizophrenia, depression and autism. Animal models of neuropsychiatric disorders have revealed the underlying microglial pathologies. In addition, various psychotropic drugs have been suggested to have direct effects on microglia. Until now, the relationship between microglia, neurotransmitters and psychiatric disorders has not been well understood. Therefore, in this review, at first, we summarize recent findings of interaction between microglia and neurotransmitters such as dopamine, serotonin, norepinephrine, acetylcholine and glutamate. Next, we introduce up-to-date knowledge of the effects of psychotropic drugs such as antipsychotics, antidepressants and antiepileptics on microglial modulation. Finally, we propose the possibility that modulating microglia may be a key target in the treatment of various psychiatric disorders. Further investigations and clinical trials should be conducted to clarify this perspective, using animal in vivo studies and imaging studies with human subjects.

UR - http://www.scopus.com/inward/record.url?scp=84878001014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878001014&partnerID=8YFLogxK

M3 - Article

C2 - 23157624

AN - SCOPUS:84878001014

VL - 20

SP - 331

EP - 344

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 3

ER -